Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Atea plunges after COVID-19 treatment fails to help patients in study

WorldOct 19, 2021 11:15AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The word "COVID-19" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration

By Mrinalika Roy and Leroy Leo

(Reuters) - Atea Pharmaceuticals Inc's experimental COVID-19 antiviral pill, being developed with Roche, failed to help patients with mild and moderate COVID-19 in a small study of mostly low-risk patients, driving the U.S. drugmaker's shares down more than 65% on Tuesday.

The trial results puts Atea and Roche far behind U.S.-based Merck & Co Inc in the race to a pill to treat COVID-19.

Atea is considering changing the target patient population for its larger, late-stage trial, making it more similar to the trial run for Merck's molnupiraivir. As a result, Atea said it will not have data from that trial until the second half of 2022, a delay of at least six months.

Merck applied for U.S. emergency use authorization for its drug last week after it was shown to cut the rate of hospitalization and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease.

Pfizer Inc (NYSE:PFE) is due to report data for its antiviral as soon as this quarter.

Atea's shares slumped about 70% to $12.15 in early trading, while Roche shares fell 1.9%. Both Merck and Pfizer shares were up about 1.5%.

Jefferies (NYSE:JEF) analyst Michael Yee said the setback was an unfortunate delay for a potentially important COVID-19 drug and will increase the emphasis on the use of vaccines.

Atea said the treatment did not show a clear reduction in SARS-CoV-2 viral load in the overall population of patients with mild or moderate COVID-19 compared to placebo in the mid-stage study.

However, the viral load reduced in high-risk patients with underlying health conditions.

Nearly two-thirds of the patients in the study had mild symptoms with no underlying health conditions, with COVID-19 vaccinated patients included in the overall study population, Atea said. The Merck trial did not include vaccinated patients.

"Having a healthier and partially vaccinated patient population with largely mild disease has important implications in determining the viral kinetics and may have made it more difficult to evaluate viral efficacy," Atea Chief Development Officer Janet Hammond said in a conference call.

The company said it was looking to modify an ongoing late-stage study testing the drug in non-hospitalized patients with mild to moderate COVID-19 to include changes to the trial's main goal and patient population.

"It's really the high risk patients where you're going to have the greatest likelihood of seeing an impact clinically," Hammond said.

Atea plunges after COVID-19 treatment fails to help patients in study
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email